Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06719011 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06719011 · ClinicalTrials.gov record · last posted 2026-08-25

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

StatusCompleted
PhasePhase 1
Started2024-12-03
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.

Protocol amendment history 3 changes detected by DataLookout

2026-08-26
Trial completed
2026-08-26
Primary completion pushed: 2026-03-26 → 2026-07-20
2026-08-26
Completion pushed: 2026-05-17 → 2026-07-20
Trial Details
NCT Number NCT06719011
Lead Sponsor Novo Nordisk A/S
Conditions Obesity, Overweight
Enrollment 178 participants
Start Date 2024-12-03
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-25